93 related articles for article (PubMed ID: 9062121)
1. Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action.
Strumberg D; Nitiss JL; Dong J; Walker J; Nicklaus MC; Kohn KW; Heddle JG; Maxwell A; Seeber S; Pommier Y
Antimicrob Agents Chemother; 2002 Sep; 46(9):2735-46. PubMed ID: 12183223
[TBL] [Abstract][Full Text] [Related]
2. A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents.
Blower TR; Bandak A; Lee ASY; Austin CA; Nitiss JL; Berger JM
Nucleic Acids Res; 2019 Sep; 47(15):8163-8179. PubMed ID: 31287876
[TBL] [Abstract][Full Text] [Related]
3. Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC.
Kloskowski T; Gurtowska N; Olkowska J; Nowak JM; Adamowicz J; Tworkiewicz J; Dębski R; Grzanka A; Drewa T
Int J Oncol; 2012 Dec; 41(6):1943-9. PubMed ID: 23042104
[TBL] [Abstract][Full Text] [Related]
4. Natural product inspired diastereoselective synthesis of sugar-derived pyrano[3,2-c]quinolones and their in-silico studies.
Arora A; Kumar S; Kumar S; Singh SK; Dua A; Singh BK
Carbohydr Res; 2024 May; 539():109105. PubMed ID: 38583285
[TBL] [Abstract][Full Text] [Related]
5. Simple and Fast DNA Based Sensor System for Screening of Small-Molecule Compounds Targeting Eukaryotic Topoisomerase 1.
Petersen KV; Selas A; Hymøller KM; Mizielinski K; Thorsager M; Stougaard M; Alonso C; Palacios F; Pérez-Pertejo Y; Reguera RM; Balaña-Fouce R; Knudsen BR; Tesauro C
Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452216
[No Abstract] [Full Text] [Related]
6. Targeting DNA Topoisomerase II in Antifungal Chemotherapy.
Kondaka K; Gabriel I
Molecules; 2022 Nov; 27(22):. PubMed ID: 36431868
[TBL] [Abstract][Full Text] [Related]
7. Lipid-derived electrophiles mediate the effects of chemotherapeutic topoisomerase I poisons.
Flor A; Wolfgeher D; Li J; Hanakahi LA; Kron SJ
Cell Chem Biol; 2021 Jun; 28(6):776-787.e8. PubMed ID: 33352117
[TBL] [Abstract][Full Text] [Related]
8. Smoothed Potential MD Simulations for Dissociation Kinetics of Etoposide To Unravel Isoform Specificity in Targeting Human Topoisomerase II.
Kuriappan JA; Osheroff N; De Vivo M
J Chem Inf Model; 2019 Sep; 59(9):4007-4017. PubMed ID: 31449404
[TBL] [Abstract][Full Text] [Related]
9. Novel xanthone-polyamine conjugates as catalytic inhibitors of human topoisomerase IIα.
Minniti E; Byl JAW; Riccardi L; Sissi C; Rosini M; De Vivo M; Minarini A; Osheroff N
Bioorg Med Chem Lett; 2017 Oct; 27(20):4687-4693. PubMed ID: 28919339
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a Cryptic Antifungal Compound from Streptomyces albus J1074 Using High-Throughput Elicitor Screens.
Xu F; Nazari B; Moon K; Bushin LB; Seyedsayamdost MR
J Am Chem Soc; 2017 Jul; 139(27):9203-9212. PubMed ID: 28590725
[TBL] [Abstract][Full Text] [Related]
11. Activity of quinolone CP-115,955 against bacterial and human type II topoisomerases is mediated by different interactions.
Aldred KJ; Schwanz HA; Li G; Williamson BH; McPherson SA; Turnbough CL; Kerns RJ; Osheroff N
Biochemistry; 2015 Feb; 54(5):1278-86. PubMed ID: 25586498
[TBL] [Abstract][Full Text] [Related]
12. Heterocycles [h]fused onto 4-oxoquinoline-3-carboxylic acid, part IV. Convenient synthesis of substituted hexahydro [1,4]thiazepino[2,3-h]quinoline-9-carboxylic acid and its tetrahydroquino[7,8-b]benzothiazepine homolog.
Al-Huniti MH; El-Abadelah MM; Zahra JA; Sabri SS; Ingendoh A
Molecules; 2007 Jul; 12(8):1558-68. PubMed ID: 17960073
[TBL] [Abstract][Full Text] [Related]
13. Bioflavonoids as poisons of human topoisomerase II alpha and II beta.
Bandele OJ; Osheroff N
Biochemistry; 2007 May; 46(20):6097-108. PubMed ID: 17458941
[TBL] [Abstract][Full Text] [Related]
14. Moxifloxacin enhances antiproliferative and apoptotic effects of etoposide but inhibits its proinflammatory effects in THP-1 and Jurkat cells.
Fabian I; Reuveni D; Levitov A; Halperin D; Priel E; Shalit I
Br J Cancer; 2006 Oct; 95(8):1038-46. PubMed ID: 17047652
[TBL] [Abstract][Full Text] [Related]
15. A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II.
Gruger T; Nitiss JL; Maxwell A; Zechiedrich EL; Heisig P; Seeber S; Pommier Y; Strumberg D
Antimicrob Agents Chemother; 2004 Dec; 48(12):4495-504. PubMed ID: 15561817
[TBL] [Abstract][Full Text] [Related]
16. Effects of tyrosine kinase inhibitors on cell death induced by sodium fluoride and pertussis toxin in the pancreatic beta-cell line, RINm5F.
Elliott J; Scarpello JH; Morgan NG
Br J Pharmacol; 2001 Jan; 132(1):119-26. PubMed ID: 11156568
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions.
Sabourin M; Osheroff N
Nucleic Acids Res; 2000 May; 28(9):1947-54. PubMed ID: 10756196
[TBL] [Abstract][Full Text] [Related]
18. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
19. Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme.
Corbett AH; Hong D; Osheroff N
J Biol Chem; 1993 Jul; 268(19):14394-8. PubMed ID: 8390992
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
